MINAPHARM Pharmaceuticals

CASE:MIPH Stock Report

Market Cap: ج.م2.2b

MINAPHARM Pharmaceuticals Past Earnings Performance

Past criteria checks 0/6

MINAPHARM Pharmaceuticals has been growing earnings at an average annual rate of 20.6%, while the Pharmaceuticals industry saw earnings growing at 5.8% annually. Revenues have been growing at an average rate of 17.1% per year.

Key information

20.6%

Earnings growth rate

22.1%

EPS growth rate

Pharmaceuticals Industry Growth9.8%
Revenue growth rate17.1%
Return on equity0.6%
Net Margin-1.4%
Last Earnings Update31 Dec 2023

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How MINAPHARM Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

CASE:MIPH Revenue, expenses and earnings (EGP Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 233,892-55726151
30 Sep 233,943191673125
30 Jun 234,00346160398
31 Mar 233,79450752576
31 Dec 223,62159047259
30 Sep 223,44254445646
30 Jun 223,21246742946
31 Mar 223,03245440147
31 Dec 213,00544838646
30 Sep 212,91842237753
30 Jun 212,75439835746
31 Mar 212,58332533743
31 Dec 202,36128532739
30 Sep 202,20027132740
30 Jun 202,11521631239
31 Mar 202,08017431940
31 Dec 192,05114131139
30 Sep 191,9178631048
30 Jun 191,9366730452
31 Mar 191,9488130659
31 Dec 181,91911629165
30 Sep 181,92815625868
30 Jun 181,82018624765
31 Mar 181,71719822054
31 Dec 171,64617520953
30 Sep 171,4936520346
30 Jun 171,3255519341
31 Mar 171,1903517946
31 Dec 161,0353317339
30 Sep 161,0238615232
30 Jun 161,0199714634
31 Mar 161,00111014529
31 Dec 159668314026
30 Sep 159168513829
30 Jun 158856113728
31 Mar 158615712826
31 Dec 148304912629
30 Sep 148077512124
30 Jun 147727111429
31 Mar 147286911628
31 Dec 137128111425
30 Sep 136875910827

Quality Earnings: MIPH is currently unprofitable.

Growing Profit Margin: MIPH is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: MIPH is unprofitable, but has reduced losses over the past 5 years at a rate of 20.6% per year.

Accelerating Growth: Unable to compare MIPH's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: MIPH is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (27.9%).


Return on Equity

High ROE: MIPH has a negative Return on Equity (0.64%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.